Drug Profile

PLT 012

Alternative Names: PLT-012

Latest Information Update: 08 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pilatus Biosciences
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cholangiocarcinoma; Liver cancer
New Molecular Entity No

Highest Development Phases

Preclinical Immunological disorders; Liver cancer; Liver metastases; Solid tumours

Most Recent Events

30 Apr 2025 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumours released by Pilatus Biosciences
25 Apr 2025 Preclinical trials in Liver cancer in Switzerland (Parenteral), prior to April 2025
25 Apr 2025 Preclinical trials in Liver metastases in Switzerland (Parenteral), prior to April 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com